BridgeBio surges on Q4 revenue beat, Phase 3 success
Attruby prescriptions jump 35% as biotech posts three positive late-stage trial results in three months
BridgeBio Pharma shares rose 0.6% in Tuesday trading after the biotechnology company reported fourth-quarter revenue that crushed analyst expectations, driven by accelerating adoption of its flagship heart drug and a flurry of positive clinical trial results.
The Palo Alto-based company reported total revenue of $154.2 million for the final quarter of 2025, beating the consensus estimate of $105.7 million by 46%. The strong commercial performance overshadowed a wider-than-expected loss of $1 per share, compared with analyst projections of a 78-cent loss.
At the heart of BridgeBio's commercial momentum is Attruby, its treatment for transthyretin amyloid cardiomyopathy, which generated $146 million in net product revenue during the quarter. That represents a 35% increase from the previous quarter, supported by 7,804 patient prescriptions as the company continues to gain market share in the competitive ATTR-CM space.
"The commercial execution on Attruby has been exceptional," analysts noted in the company's earnings review, highlighting the drug's ability to capture physician demand despite competition from established players in the cardiac amyloidosis market.
Beyond commercial progress, BridgeBio's clinical pipeline delivered a remarkable three-for-three batting average with positive Phase 3 readouts across three separate programs within just three months. The successes included BBP-418 for limb-girdle muscular dystrophy, encaleret for autosomal dominant hypocalcemia, and infigratinib for cholangiocarcinoma.
The company plans to submit new drug applications for all three programs between the first and second halves of 2026, setting up a potentially transformational period for the company's regulatory profile. BridgeBio ended the quarter with $587.5 million in cash and an additional $632.5 million in convertible notes, providing substantial runway to fund these upcoming regulatory submissions and potential commercial launches.
Analysts remain overwhelmingly bullish on BridgeBio's prospects, with 21 of 22 covering analysts rating the stock a buy or strong buy and a consensus price target of $98.38—44% above the current share price of $68.31. The stock has surged 141% over the past year, outperforming the broader biotechnology sector as investors have warmed to the company's commercial execution and pipeline de-risking.
BridgeBio's market capitalization now stands at approximately $13 billion, reflecting investor confidence in a company that has successfully transitioned from a clinical-stage biotech to a commercial operation with multiple late-stage assets. Institutional ownership exceeds 100% of the float, indicating strong demand from professional investors.
The company faces challenges ahead, including competition from Pfizer and Alnylam in the ATTR-CM market, as well as the execution risk associated with preparing three separate NDA submissions within a compressed timeframe. However, the strong cash position and demonstrated commercial capabilities provide a solid foundation for BridgeBio's ambitious growth plans.
With full-year 2025 revenue reaching $502.1 million, BridgeBio has established itself as a meaningful player in the genetic disease space. The coming year will prove critical as the company attempts to convert its clinical successes into regulatory approvals and expanded commercial opportunities, potentially justifying the premium valuation assigned by Wall Street.